Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEX12T)

Drug Name

FC EPO Drug Info

Synonyms

Long acting erythropoietin (anemia), Merck Serono

Indication

Disease Entry	ICD 11	Status	REF
Anemia	3A00-3A9Z	Discontinued in Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Erythropoietin (EPO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MK-2578	DM1M57I	Anemia	3A00-3A9Z	Phase 2	[3]
LKA651	DMCFGP3	Diabetic macular edema	9B71.02	Phase 2	[4]
Erythropoietin-transfected autologous cell therapy	DMNZ6VA	Anemia	3A00-3A9Z	Phase 1/2	[5]
Long-acting erythropoietin conjugate	DM9OA35	Anemia	3A00-3A9Z	Phase 1	[6]
GC-1113	DMK96CE	Anemia	3A00-3A9Z	Phase 1	[7]
GLY-515n	DM0IKB4	Cerebrovascular ischaemia	8B1Z	Terminated	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027346)
2	Detection of EPO-Fc fusion protein in human blood: screening and confirmation protocols for sports drug testing. Drug Test Anal. 2012 Nov;4(11):818-29.
3	Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636.
4	Clinical pipeline report, company report or official report of Novartis.
5	Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther. 2009 Feb;17(2):369-72.
6	Company report (Pharmexcil)
7	A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia. Arch Pharm Res. 2012 May;35(5):757-9.
8	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027536)